Visualization of inflammation in COVID-19 patients

PET/CT with 68Ga-IL2 for imaging IL2R+ cells in COVID-19+ patients - 68Ga-IL2 imaging in COVID-19

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2020-001749-38-IT

Enrollment

Registered

2020-07-01

Start date

2020-10-02

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evaluation of the inflammatory infiltrate in patients with COVID-19 in order to map the "trafficking" of T-activated lymphocytes and clarify the causes of lymphopenia

Interventions

Product Name: Radiolabelled interleukin 2 Product Code: 68Ga-IL2 Pharmaceutical Form: Solution for solution for injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age =18 years. • Diagnosis of COVID-19 obtained by means of a swab performed at the University Hospital of Sant'Andrea. • Interstitial pneumonia (unilateral / bilateral, moderate / severe) diagnosed by CT scan • Laboratory exams at registration: or WBC =65 years) yes F.1.3.1 Number of subjects for this age range 2

Exclusion criteria

Exclusion criteria: Age less than 18 years, pregnant women, absence of interstitial pneumonia

Design outcomes

Primary

Measure	Time frame
Main Objective: Evaluation of the inflammatory infiltrate in patients with COVID-19 in order to map the "trafficking" of T-activated lymphocytes and clarify the causes of lymphopenia;Secondary Objective: To verify if PET / CT with 68Ga-IL2 can be used to predict the prognosis of these patients and to select, more early and in a non-invasive way, those subjects candidates to receive invasive and targeted treatments. Correlate the uptake of 68Ga-IL2 with the different subpopulations of T-activated lymphocytes;Primary end point(s): Evaluation of the inflammatory infiltrate in patients with COVID-19 in order to map the "trafficking" of T-activated lymphocytes and clarify the causes of lymphopenia;Timepoint(s) of evaluation of this end point: 3 hour (one day examination)	—

Measure

Time frame

Main Objective: Evaluation of the inflammatory infiltrate in patients with COVID-19 in order to map the "trafficking" of T-activated lymphocytes and clarify the causes of lymphopenia;Secondary Objective: To verify if PET / CT with 68Ga-IL2 can be used to predict the prognosis of these patients and to select, more early and in a non-invasive way, those subjects candidates to receive invasive and targeted treatments. Correlate the uptake of 68Ga-IL2 with the different subpopulations of T-activated lymphocytes;Primary end point(s): Evaluation of the inflammatory infiltrate in patients with COVID-19 in order to map the "trafficking" of T-activated lymphocytes and clarify the causes of lymphopenia;Timepoint(s) of evaluation of this end point: 3 hour (one day examination)

—

Secondary

Measure	Time frame
Secondary end point(s): Biodistribution data 68Ga-IL2 in patients with COVID-19;Timepoint(s) of evaluation of this end point: 3 hour (one day examination)	—

Countries

Italy

Contacts

Public ContactAlberto Signore

Azienda Ospedaliero-Universitaria S. Andrea

alberto.signore@uniroma1.it00390633775538

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026